This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Marinus Pharmaceuticals (MRNS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Actinium (ATNM) Stock Jumps 8.6%: Will It Continue to Soar?
by Zacks Equity Research
Actinium (ATNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -13.98% and 20.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 100% and 11.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?
by Zacks Equity Research
ChemoCentryx (CCXI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -13.04% and 5.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Marinus Pharmaceuticals (MRNS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder
by Zacks Equity Research
The FDA approves Marinus' (MRNS) Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. The company's shares gain following the announcement.
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sigilon Therapeutics, Inc. (SGTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -19.57% and 47.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD (TXMD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -50% and 37.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 412.50% and 3.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 13.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 30.26% and 335.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.41% and -25.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 16th
by Zacks Equity Research
JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021
New Strong Sell Stocks for July 9th
by Zacks Equity Research
BEST, JRSH, MRNS, MFGP and SABR have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2021.
New Strong Sell Stocks for June 21st
by Zacks Equity Research
ASTE, CMTL, EBMT, MRNS and WRE have been added to the Zacks Rank #5 (Strong Sell) List on June 21, 2021.
New Strong Sell Stocks for June 4th
by Zacks Equity Research
ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -60.87% and -30.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -5.77% and -12.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study
by Zacks Equity Research
Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.